16 East 34th Street floor 10
Tel: +1 510-545-3803
About Formation Bio
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture.
Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater value per program and accelerating access to new treatments for patients.
Join our culture of innovation where your work directly contributes to transforming patient care in areas such as rheumatology, dermatology, CNS, and cardiometabolic diseases. Our dynamic environment blends advanced technology with strategic drug development, speeding up the delivery of new treatments. Here, every role plays a part in our mission to bring new treatments to patients faster and more efficiently.
8 articles about Formation Bio
TrialSpark Rebrands as Formation Bio, Continuing Its Commitment to Advancing Drug Development Innovation
TrialSpark, a tech-driven drug developer with its own portfolio of clinical stage drug assets, is rebranding to Formation Bio.
TrialSpark and Sanofi announced a new partnership to expedite drug development for areas with high unmet needs by licensing or acquiring six mid-to-late-stage drug candidates.
TrialSpark announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies
TrialSpark announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently.
TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio
TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany.
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here's a look.
This week, three global biopharmaceutical companies received over half a billion dollars to support research and development initiatives in the treatment of rare and deadly diseases.
TrialSpark's technology-enabled clinical trial platform is uniquely equipped to run challenging trials faster and more efficiently by increasing patient access to investigational medicines and dramatically expediting patient recruitment timelines
TrialSpark Inc., a tech-enabled drug development company dedicated to improving the speed, quality, and innovation of clinical trials, announces the addition of life sciences veteran Steve Holtzman as a key strategic advisor